Bridging the Headache Divide: How Asia and the World Unite for Better Brain Health
"Discover how collaborative efforts between Asian and international headache societies are paving the way for advancements in diagnosis, treatment, and awareness of headache disorders."
Headache disorders pose a significant public health challenge worldwide, yet the burden is particularly pronounced in Asia, home to nearly 60% of the world's population. Cultural stigmas, varying healthcare landscapes, and limited awareness often contribute to underdiagnosis and inadequate management of these conditions. Recognizing the urgent need for a targeted approach, the Asian Regional Consortium for Headache (ARCH) has emerged as a vital force in advocating for headache sufferers across the continent.
Since its inception, ARCH has been dedicated to fostering collaboration among headache specialists in Asia, promoting research, and raising awareness of headache disorders among both healthcare professionals and the general public. ARCH works in close partnership with the International Headache Society (IHS), leveraging global expertise and resources to address the specific challenges faced by Asian populations.
This article delves into the collaborative efforts between ARCH and IHS, highlighting key initiatives aimed at improving the diagnosis, treatment, and overall management of headache disorders in Asia. By bridging the gap between global knowledge and local needs, these organizations are paving the way for a brighter future for millions of individuals affected by headaches in the region and worldwide.
Measuring Asia’s Headache Burden
A 2025 study used data from the Global Burden of Disease (GBD) 2021 database to assess the incidence, prevalence, and disability-adjusted life years (DALYs) of migraine and tension-type headache in Asia from 1990 to 2021. It examined differences by year, age, sex, and country, as well as correlations with sociodemographic indices. The supplied source summaries describe the study’s methods but do not provide its numerical findings.
A Long History of Headache Care
A 2020 historical review analyzed 27 headache types, identifying when each was first described and the author and country associated with that description. Its conclusion emphasizes that headache treatment history did not begin with triptans: the source also notes that propranolol’s approval for migraine prevention and dihydroergotamine’s introduction were not the first milestones in prevention. Traditional remedies remain part of this wider history; the cited chapter describes acupuncture and herbs as main approaches in China and Ayurveda in India.
Addressing Unique Challenges in Asia: ARCH and IHS Initiatives
ARCH, in collaboration with the IHS, is actively working to combat these challenges through several key initiatives. These initiatives are designed to address the unique needs and cultural contexts of Asian populations, while aligning with global standards and best practices in headache management.
- Promoting the adoption and implementation of the International Classification of Headache Disorders (ICHD)
- Providing educational resources and training programs for healthcare professionals to improve their understanding of headache diagnosis
- Encouraging research to identify specific diagnostic markers and subtypes of headache disorders prevalent in Asian populations
Traditional and Western Prescribing in East Asia
A review of migraine prevalence, burden, and clinical management in China, Japan, and South Korea reports that Japanese clinicians prescribe traditional patent medicines alongside Western prescription medicines for various types of pain, including headache and migraine. It also cites an analysis of the China Health Insurance Association (CHIRA) medical insurance claims database, which found that approximately 25% of patients were prescribed Chinese patent medicine for migraine. These examples describe prescribing practices reported in the review, not evidence that the treatments have equivalent effectiveness.
Limits in Evidence and Comparability
A systematic review found no migraine diagnostic tool for nonclinical settings supported by high-quality evidence; the HARDSHIP questionnaire, ID-migraine, and structured headache questionnaire had moderate-quality evidence, while evidence for the remaining tools was poor quality. A separate review of complementary and alternative medicine (CAM) for headache describes its relevance in Asian countries where cost limits access to newer medications and treatment is influenced by local culture. One qualitative analysis cited in the supplied material reported that wet cupping plus drugs could quickly relieve pain and improve quality of life, but that report alone does not establish broad effectiveness. A review of cluster headache set out to compare clinical features in Asian populations with those in Europe and North America, noting that geographic and ethnic differences are discussed more often for migraine than for cluster headache.
Different Measures, Different Estimates
A Japanese claims-data study found that sensitivity varied from 7.3% for Algorithms 9 and 11 to 13.5% for Algorithm 2 when identifying people with migraine; the lower-sensitivity algorithms required repeated migraine or tension-type headache diagnostic records and a same-month prescription record for migraine prophylaxis or triptans. An Asian Migraine Criteria validation study, using ICHD-II as the gold standard, reported sensitivity of 99.3%, specificity of 84.5%, positive predictive value of 96.9%, negative predictive value of 96.1%, and validity of 96.8% for adult migraine diagnosis. A 2003 epidemiology review reported migraine prevalence ranging from 8.4% to 12.7% in studies other than the Korean study and first Hong Kong study (1992–1993). A separate Asia-Pacific systematic review reported chronic daily headache prevalence of 1.0–3.9% in population studies, with a median of 2.9%; these figures describe a different headache measure and should not be treated as migraine prevalence.
A Unified Vision for Headache Care
The collaboration between ARCH and the IHS exemplifies the power of international partnerships in addressing global health challenges. By combining local expertise with global resources, these organizations are making significant strides in improving the lives of individuals affected by headache disorders in Asia and beyond.
What the Herbal-Medicine Review Reports
A 2019 systematic review identified 30 randomized controlled trials involving 3,447 people with headache, including migraine, tension-type headache, and chronic daily headache. The review’s main findings indicated that Chinese herbal medicine (CHM) used alone was superior to placebo on several reported outcomes: headache frequency, headache days, duration, and intensity, as well as analgesic use. These are findings reported by the review; the supplied summary does not give effect sizes or further details about the trials.
A Real-World Study of OTC Headache Treatments
A real-world evidence study published in February 2025 investigated three over-the-counter (OTC) headache treatments. It examined their effects on headache intensity and associated cognitive and functional impairment across three geographies. The supplied source summary does not name the treatments or geographies, or report the study’s results.
The journey toward better headache care in Asia is ongoing, but the commitment and dedication of ARCH and the IHS provide a solid foundation for future progress. As these organizations continue to work together, they will undoubtedly pave the way for innovative solutions, improved access to care, and a brighter future for headache sufferers in the region.
Like the song, 'Bridge over troubled water', the joint action of the IHS and ARCH will serve as a strong BOARDWALK over many harsh headache issues.